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Abstract
TRIM32 is a E3 ubiquitin -ligase containing RING, B-box, coiled-coil and six C-terminal NHL domains. Mutations
involving NHL and coiled-coil domains result in a pure myopathy (LGMD2H/STM) while the only described
mutation in the B-box domain is associated with a multisystemic disorder without myopathy (Bardet-Biedl
syndrome type11), suggesting that these domains are involved in distinct processes. Knock-out (T32KO) and knock-
in mice carrying the c.1465G > A (p.D489N) involving the NHL domain (T32KI) show alterations in muscle regrowth
after atrophy and satellite cells senescence. Here, we present phenotypical description and functional
characterization of mutations in the RING, coiled-coil and NHL domains of TRIM32 causing a muscle dystrophy.
Reduced levels of TRIM32 protein was observed in all patient muscle studied, regardless of the type of mutation
(missense, single amino acid deletion, and frameshift) or the mutated domain. The affected patients presented with
variable phenotypes but predominantly proximal weakness. Two patients had symptoms of both muscular
dystrophy and Bardet-Biedl syndrome. The muscle magnetic resonance imaging (MRI) pattern is highly variable
among patients and families. Primary myoblast culture from these patients demonstrated common findings
consistent with reduced proliferation and differentiation, diminished satellite cell pool, accelerated senescence of
muscle, and signs of autophagy activation.
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Introduction
Tripartite motif-containing protein 32 (TRIM32) is an
E3 ubiquitin ligase, whose activity is contained in the
RING finger domain of the tripartite TRIM/RBCC motif
(RING, B-box, coiled-coil) [20, 30]. In addition, TRIM32
has six C-terminal NHL domains. The majority of the
mutations described in TRIM32 are clustered in the
C-terminal NHL domain, which is defined by amino acid
sequence homologies to regions of Ncl-1, HT2A and
Lin-41 proteins, supporting its role in protein-protein
interactions, critical for the ubiquitination process [13,
29, 44]. Mutations involving the NHL and coiled-coil
domains are associated with limb-girdle muscular dys-
trophy 2H (LGMD2H) and sarcotubular myopathy
(STM), which are considered as a continuum [15, 21].
Until now, only one mutation has been described involv-
ing the B-box domain, resulting in a different multisyste-
mic disorder called Bardet-Biedl syndrome (BBS) type 11
with no skeletal muscle involvement, in an only family
with four affecting siblings [7]. No mutations in the
RING finger domain have been reported.
Proximal weakness is the characteristic feature of
LGMD2H/STM, although other clinical findings, such as
facial, axial or distal weakness, can be associated [5, 15,
19, 28, 33, 34, 39, 42]. Pathologically LGMD2H/STM are
characterized by segmental vacuolation of the sarcoplas-
mic reticulum and transverse tubules [42], however vac-
uoles containing basophilic material consistent with
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autophagic vacuoles have also been observed in the
muscle biopsy of these patients [21, 28]. The mutation
c.1459G > A/p.D487N in the TRIM32 gene, identified as
a founder mutation in Hutterite population, has been
the most frequently reported [15], but a recent series of
12 non-Hutterite patients with a TRIM32-related myop-
athy, with mutations located both in the NHL and
coiled-coil domains, has been described [21].
A yeast model has shown that TRIM32 mutations in-
volving the NHL domain introduce conformational
changes that impair the interaction properties of the
protein, and consequently the ubiquitination process
[39]. The most relevant mechanistic studies have been
performed in the Trim32 knockout (T32KO) and the
knock-in mice carrying the Hutterite mutation (T32KI)
[25, 26]. TRIM32, as a ubiquitous E3 ubiquitin ligase,
has been demonstrated to promote degradation of sev-
eral targets [1, 8, 18, 22, 24, 29, 31, 37], so the absence
or abnormal function of TRIM32 due to recessive muta-
tions would lead to loss of ubiquitination and accumula-
tion of the TRIM32 substrates. E3 small
ubiquitin-related modifier (SUMO) ligase (PIAS4) [1]
and N-myc down-regulated protein 2 (NDRG2) have
been previously identified as important TRIM32 sub-
strates. Overexpression of PIAS4 is implicated in regula-
tion of cellular senescence [4] and TRIM32-deficient
primary myoblasts from T32KO mice have been demon-
strated to undergo premature senescence and impaired
myogenesis due to accumulation of PIAS4 [23]. On the
other hand, NDRG2 overexpression in C2C12 myoblasts
reduces cell proliferation and delayed cell cycle with-
drawal during differentiation [14, 31]. Altogether, these
results coming from cell and animal models, support the
hypothesis that TRIM32 is involved in control of myo-
genesis and that premature senescence underlies myop-
athy in LGMD2H.
T32KI mice demonstrated that the Hutterite mutation
(p.D489N) causes TRIM32 protein degradation, but this
finding has not been reported in muscle from patients
carrying missense mutations [25]. There is evidence that
the EI24 autophagy-associated transmembrane protein is
involved in the degradation of RING E3 ligases using the
autophagy machinery, establishing a connection between
two major protein degradation mechanisms, autophagy
and the ubiquitin-proteasome system [11]. However, no
specific studies about the role of autophagy in the deg-
radation of TRIM32 have been reported.
We aimed to establish if patients with muscular dys-
trophy due to TRIM32 mutations show evidence for the
pathogenic mechanism postulated in the mouse models.
This would provide a potential set of functional assays.
We studied the muscle and myoblasts from three fam-
ilies with mutations in the NHL, coiled-coil and RING
domains of TRIM32 resulting in a null-phenotype. We
demonstrated common findings consistent with prema-
ture senescence, reduced myoblast proliferation and dif-
ferentiation and, in addition, signs of autophagy
activation seemingly involved in the degradation of the
mutated TRIM32.
Materials and methods
Genetic work-up
DNA was extracted from blood using standard proce-
dures. Patients were studied using next generation se-
quencing (NGS): patient IV.3/Family A and patient II.2/
Family C with a panel of 34 genes associated with auto-
somal recessive limb-girdle muscular dystrophies, and
patient II.3/Family B with a panel of 256 neuromuscular
disease genes using HighSeq and NextSeq Illumina plat-
forms. Affected and unaffected relatives of the probands
were screened for their family mutations by Sanger
sequencing.
Histological studies
Muscle samples were obtained by open muscle biopsies
from the biceps brachii muscle of the three patients
from Family A (III.2, IV.3 and III.3), two patients from
Family B (II.2 and II.3), one patient from Family C (II.2),
five aged-matched healthy controls and four
age-matched disease controls (LGMD1B, LGMD1C,
LGMD2N, NEM6). Frozen muscle sections were stained
for standard histological and histochemical techniques
including hematoxylin and eosin (H&E) and neonatal
myosin heavy chain (MHC-neo). Stained sections were
evaluated with an Olympus BX41 (Tokyo, Japan)
equipped with a ColorView IIIu camera (Olympus).
Primary cell culture
Myoblasts from Family A (III.2 and IV.3), Family B (II.2
and II.3) and seven aged-matched healthy controls and
three age-matched disease controls (LGMD2B, and
X-EDMD) were used for the experiments. Fresh muscle
samples were minced and cultured in a monolayer.
Briefly, the culture medium for the myoblast stage (pro-
liferation medium) contains 75% Dulbecco’s minimal es-
sential medium (DMEM, Invitrogen) and 25% M199
medium (Invitrogen), supplemented with 10% fetal bo-
vine serum (FBS), 10 μg/ml insulin, 2 mM glutamine,
100 units/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/
ml fungizone, 10 ng/ml epidermal growth factor, and 25
ng/ml fibroblast growth factor. To obtain highly purified
myoblasts, each 107 cells were mixed with 20 μl of
CD56-coated microbeads (Milteny Biotec, Bergisch
Gladbach, Germany) and incubated at 4 °C for 15 min.
Unbound microbeads were removed by washing cells in
excess PBS buffer followed by centrifugation at 400×g
for 10 min. The cell pellet was resuspended in PBS buf-
fer to a concentration of 2 × 108 cells/ml before
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separation on a midiMACS cell separator (Milteny Bio-
tec, Bergisch Gladbach, Germany).
Transmission Electron microscopy (TEM)
A piece of muscle from each biopsy and primary myo-
blast from patients and controls were fixed in 2,5% glu-
taraldehyde in 0,1 M sodium cacodylate buffer (pH 7,4)
for 3 h at 4 °C, washed with the same buffer, postfixed in
1% osmium tetraoxide in 0,1M cacodylate buffer (pH
7,4) for 1 h at 4 °C, and then rinsed with distilled water.
Samples were immersed in 2% uranyl acetate, dehy-
drated through a gradient acetone series (50, 70, 90 and
100%), and embedded in Spurr’s resin. Semithin sections
(450 nm thickness) were obtained with a glass knife and
stained with 1% toluidine blue for muscle fiber/myoblast
localization and reorientation using a conventional optic
microscope. Once a suitable block face of the selected
area was trimmed, ultrathin sections (70 nm) were ob-
tained using an ultramicrotome (Leica UC7) equipped
with a diamond knife (Diatome) and collected on 200
mesh copper grids. Sections were viewed with a Zeiss
Libra 120 transmission electron microscope (Carl Zeiss
NTS GmbH, Oberkochen, Germany).
Scanning Electron microscopy (SEM)
Primary myoblasts from patients and controls were fixed
with 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer (pH 7.4) for 3 h at 4 °C and postfixed in 1% os-
mium tetraoxide in 0,1M cacodylate buffer (pH 7.4) for
1 h at 4 °C. Samples were then dehydrated through a
graded series of acetone solutions, critical point dried,
gold sputtered, and examined with a Zeiss Auriga Field
Emission Scanning Electron Microscope (Carl Zeiss
NTS GmbH, Oberkochen, Germany).
Immunohistochemical studies
Cultured primary myoblasts from patients and controls
were fixed with 4% paraformaldehyde for 30min, perme-
abilized in 0.2% Triton X-100 for 10min and incubated in
1% BSA/PBS for 45min. The following primary antibodies
were used: rabbit polyclonal anti-TRIM32 (NBP1–33737)
(1:500; Novus Biologicals); rabbit monoclonal anti-Desmin
(D93FD5) (1:100; Abcam); mouse monoclonal anti-Ki67
(B56) (1:200; BD Biosciences); mouse monoclonal
anti-Myogenin (FD5) (1:100; Abcam) and incubated for
12 h at 4 °C. Frozen muscle samples were fixed with 4%
PFA for 15min and immersed in citrate buffer (pH 6) for
30min at 80 °C and washed with PBS. Afterward, muscle
samples were blocked with 2% non-fat milk + 0.3% Triton
X-100 in PBS for 30min and with 5% BSA + 0.5% Triton
X-100 in PBS for 1 h. The following primary antibodies
were used: mouse monoclonal anti-Pax7 (1:50; DHSB);
mouse monoclonal anti-collagen VI (3C4) (1:1000; Che-
micon) and incubated for 3 days at 4 °C. After washing,
samples were incubated with the secondary antibodies
conjugated with Cy2 and Cy3 (1:500; Jackson ImmunoRe-
search) for 1 h. Finally, the nuclei were stained for 20min
with To-pro-3-Iodide (Topro 3) at 1/1000 in PBS and the
slides were coverslipped with fluorescence mounting
medium (Dako). Images were acquired on a Zeiss LSM
710 confocal laser scanning microscope using 20 x object-
ive with a numerical aperture of 1.3. Images from controls
and patients were obtained at the same day and under
equal conditions (laser intensities and photomultiplier
voltages). Maximal projections of Z-stacked images were
analyzed with ImageJ software (RRID:SCR_003070).
Senescence-associated β-galactosidase (SA-β-gal) staining
Cell senescence was assessed measuring SA-β-gal activity at
pH 6.0 [12]. Primary patient myoblasts were fixed in 0.2%
glutaraldehyde for 15min at room temperature and stained
in solution containing 1mg/ml bromo-chloro-indolyl-ga-
lactopyranoside (X-gal), 40mM citrid acid/sodium phos-
phate (pH 6), 5mM potassium ferrocyanide, 5mM
potassium ferricyanide, 150mM sodium chloride, 2mM
magnesium chloride. SA-β-gal+ cells were detected by
phase contrast microscopy using Olympus Inverted Micro-
scopes Models IX71.
Western blot analysis
Frozen muscle samples and primary patient myoblasts
were homogenized in RIPA buffer (20 mM Tris HCl pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL, 0.1% SDS)
containing protease inhibitor cocktail (Roche). Western
blot analysis of equal-protein loading were performed
with the following primary antibodies: rabbit polyclonal
anti-TRIM32 (NBP1–33737) (1:500; Novus Biologicals);
mouse monoclonal anti-Myogenin (FD5) (1:100;
Abcam); mouse monoclonal anti-Myosin Heavy Chain
(A4.1025) (1:500; Millipore); rabbit polyclonal anti-LC3B
(1:1000; Cell Signaling), rabbit monoclonal anti-LAMP1
(D2D11) (1:1000; Cell Signaling) and rabbit polyclonal
anti-GAPDH (1:2000; Sigma-Aldrich). Immunoreactivity
was detected with secondary antibodies conjugated to
horseradish peroxidase (1:5000; Jackson Immuno Re-
search) and developed with SuperSignal West Femto
(Thermo Fisher Scientific) using an ImageQuant LAS
4000 MiniGold System (GE Healthcare Life Sciences).
Proliferation and differentiation assays
CD56-positive cells were seeded at 15,000 cells/cm2
using proliferation medium. We examined proliferation
over a period of time from 0 to 8 days. The average
number of cells for each time point (0, 4, and 8 days)
was then calculated and the values were used to plot
growth curves. When the myoblasts started to fuse, the
medium was substituted with one containing 2% of FBS
without growth factor to induce differentiation. We
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measured the fusion index 4 days after medium change
by calculating the mean percentage of nuclei in myo-
tubes, relative to the total number of nuclei (myoblasts
+ myotubes).
Autophagy blockade experiment
Bafilomycin A1 (Baf-A1), an autophagosome-lysosome
fusion inhibitor, inhibits autophagy by preventing the fu-
sion of the lysosome to the autophagosome [46]. Myo-
blasts after 4 days in proliferation medium were
incubated with 1 μM Baf-A1 (Cayman) for 6 h, followed
by lysis and western blot analysis.
Statistical analysis
Graphpad Prism software (RRID: SCR_002798) was used
to analyze the data using one-way ANOVA. When the
ANOVA analysis revealed significant differences, the
post hoc Bonferroni’s test was used for pairwise compar-
isons. When parametric assumptions were not met,
Kruskal-Wallis followed by the post hoc Dunn’s test
were used. Data were plotted as mean ± SEM.
Results
Mutations in NHL, coiled-coil and RING domains of
TRIM32 are found in patients with a muscular dystrophy
We studied three independent families of Spanish and
Australian origin with a muscular dystrophy (Fig. 1a),
and identified four novel TRIM32 mutations located
in three different domains; NHL, coiled-coil and
RING domains. Patients II.2, II.3 and III.3 from fam-
ily A were homozygous for TRIM32 c.1771G > A
(p.V591M) involving the fourth NHL repeat. None of
the six healthy relatives studied from three different
generations were homozygous for the mutation,
whose frequency in gnomAD was 0.002%. Patients
II.1, II.2, II.3 and II.4 from family B were compound
heterozygous for c.650 A > G (p.N217S) and
c.1701_1703del (p.F568del) mutations, involving the
coiled-coil and fourth NHL repeat respectively. The
unaffected mother was heterozygous for the c.650
A > G (p.N217S) mutation and the father was not
available, thus the mutations were estimated likely to
be in trans. Both mutations were very rare in the
population (0.002 and 0.0003% in gnomAD respect-
ively). Patients II.2, II.3 and II.4 from Family C were
homozygous for a TRIM32 c.115_116insT
(p.C39LfsX17) mutation, involving the RING domain
(Fig. 1b). Segregation analysis demonstrated that the
variant was found in heterozygous state in the rest of
the healthy relatives studied from different genera-
tions, and was absent from the gnomAD control
population.
Distinct clinical and radiological features are identified in
all families
All patients from Family A presented with foot drop as the
first manifestation in their teens. This was the only symp-
tom for years. Over further time, they developed remark-
able ankle contractions. Later, they also developed proximal
and distal weakness in lower and upper limbs. The youn-
gest patient (IV.3) showed a more severe progression, with
need of support for gait in his thirties (Fig. 1c).
In Family B, there was a remarkable clinical variability.
Patient II.3 presented in her twenties with foot drop and
proximal upper limb weakness. At age 55, she also had
proximal lower limb weakness, and at age 58 she was
unable to walk unsupported. Patient II.2, came to our at-
tention at the age of 57, after the diagnosis of her sister
and although she did not have any complains, examin-
ation showed mild bilateral proximal upper and lower
limb weakness. Patient II.4 showed proximal and distal
lower limb weakness at age 57 and patient II.1 showed
normal physical exam at age of 67.
Patients from Family C, presented with limb-girdle
muscle weakness with onset between third and fourth
decade and later developed distal limb weakness (Fig. 1c).
Interestingly, patients II.3 and II.4 presented additional
systemic manifestations typically described in BBS includ-
ing hypogonadism, hearing loss, and behavioral abnormal-
ities (depression and obsessive-compulsive disorder).
(See figure on previous page.)
Fig. 1 Pedigrees, genetic findings and clinical features of three families with mutations in TRIM32. a Pedigree of Spanish family (family A) having
the missense c.1771G > A (p.V591M) mutation that segregates with the disease: homozygous only in affected patients. Pedigree of Australian
family (family B) presenting the missense c.650A > G (p.N217S) mutation in combination with the frameshift c.1701_1703del (p.F568del) mutation
that segregate with the disease: compound-heterozygosity only in affected patients. Pedigree of Spanish family (family C) possessing the
homozygous frameshift mutation c.115_116insT (p.C39LfsX17) that segregates with the disease: homozygous only in affected patients. In the
non-affected siblings (red symbols) of the three pedigrees we found only one or no mutated alleles. Circles denote female members and squares
male members. Double line denotes a consanguineous marriage. Solid black symbols denote affected patients. b. Chromatograms display the
homozygous missense c.650A > G (p.N217S), heterozygous missense c.650A > G (p.N217S), heterozygous frameshift c.1701_1703del (p.F568del)
and homozygous frameshift mutations in the TRIM32 gene. Arrows indicate the location of the base change. The TRIM32 functional domains
RING finger domain, B-box type 1 domain, coiled-coil region, and six NHL repeats are represented in the scheme, where arrows indicate the
novel mutations location in the TRIM32 protein structure. c. Distal muscle involvement led to distal atrophy and ankle contractions. Patient II.3
from Family C showed mild paravertebral muscle atrophy with no scapular winging. d. Muscle MRI T1-weighted axial images at gluteus, thigh
and calf levels showed different patterns of muscle involvement in the three families
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No cardiac or respiratory involvement was found in
any of the examined patients.
Muscle MRI revealed different patterns of muscle in-
volvement in the three families (Fig. 1d). Family A
showed diffused fatty degeneration in the thighs and
lower legs. Family B displayed a more focal pattern of
fatty replacement mainly involving the biceps femoris
and semimembranosus muscle in the thigh and mildly
Fig. 2 Reduced TRIM32 protein level associated with p.V591M, p.N217S/F568del and p.C39LfsX17 mutations. a, bWestern blot analysis of a muscle
derived from biopsies of family A patients, family C patient and healthy controls, and b primary myoblasts from family A patients, family B patient, and
healthy controls. Anti-TRIM32 antibody revealed a remarkable reduction of TRIM32 protein level in TRIM32V591M, TRIM32N217S/F568del and TRIM32C39LfsX17
samples compared with controls. An anti-GAPDH blot is shown as a loading control. Arrows indicate the correct band at 72 kDa. c. Immunofluorescence
staining and quantification of the percentage of TRIM32+ cells (arrowheads) in primary myoblasts at 8 days growing in proliferation medium from family A
patients (n= 2), family B patients (n= 2) and healthy controls (n= 7). Images show TRIM32 fluorescence (red). Cells were counterstained with Topro 3 (blue)
to visualize the nuclei. The percentage of TRIM32+ cells was significantly lower in TRIM32V591M and TRIM32N217S/F568del myoblasts than in controls. Data
from 9 to 31 independent fields were analyzed per condition. Mean ± SEM; Kruskal-Wallis with Dunn’s multiple comparison test. Scale bar, 50 μm
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in the soleus muscle in the lower legs. Interestingly, the
asymptomatic patient II.1 did show moderate fat re-
placement of muscles. Family C showed predominant
degeneration of the gluteus muscles, the posterior com-
partment in the thighs, and the soleus and gastrocne-
mius muscles in the lower legs.
TRIM32 gene mutations lead to a reduced TRIM32 protein
level
At present, most TRIM32 reported mutations are clustered
in the highly conserved C-terminal NHL domain of
TRIM32 and may cause conformational changes in the
protein that lead to a substantial decrease in its stability.
This hypothesis is supported by the reduced level of
TRIM32 found in human fibroblasts isolated from
LGMD2H patients carrying the homozygous p.D487N sub-
stitution and in the muscle from the mouse model T32KI
(harboring the p.D489N substitution) [1, 25]. Based on
these observations, we analyzed the effect of the novel mu-
tations on the presence of TRIM32 in muscle samples from
patients. Western blot revealed almost undetectable
TRIM32 protein level in TRIM32C39LfsX17 muscle, which
was an expected result because it is a frame-shift mutation
resulting in a premature stop codon, which in turn should
result in a severely truncated TRIM32 protein. However,
we also found a remarkable reduction of TRIM32 level in
TRIM32V591M and TRIM32N217S/F568del muscles or primary
myoblasts, compared to controls (Fig. 2a-b). Nicklas et al.
found that proliferating mouse myoblasts in culture dis-
played nuclear TRIM32 signal and a shift of TRIM32 to the
cytoplasm during differentiation [35]. In human samples,
immunostaining assay showed a reduced amount of prolif-
erating myoblasts with positive signal of TRIM32 in the nu-
clei of TRIM32V591M and TRIM32N217S/F568del myoblasts
(Fig. 2c). These data support that not only the frameshift in
the RING domain but also the single amino acid deletion
and missense TRIM32mutations identified in the NHL and
coiled-coil domains resulted in reduced levels of TRIM32
protein.
Mutations in TRIM32 impair proliferation and myogenic
differentiation in primary myoblast
Data from T32KO mice shows that TRIM32 is necessary
for proliferation and differentiation of satellite cells
through the regulation of the transcription factor c-Myc
[35], and that the loss of TRIM32 function deregulates
these processes due to the accumulation of TRIM32
substrates involved in myoblast proliferation and myo-
genesis [31]. We studied whether loss of protein due to
TRIM32 human mutations alter myoblast proliferation
in vitro. To address this point, primary myoblasts from
patients carrying p.V591M and p.N217S/p.F568del mu-
tations were cultured. The cell proliferation rate (Fig. 3a)
and percentage of Ki67+ cells (Fig. 3b) were significantly
lower in mutant myoblasts compared with controls.
Next, we investigated if muscle differentiation was also
altered when TRIM32 is reduced. The confluent myo-
blasts were cultured in differentiation medium, in which
myoblasts withdraw from the cell cycle, cease to divide,
and start to elongate and fuse to form multinucleated
myotubes. Myogenin expression (Fig. 4a-b) and fusion
index (Fig. 4c) were reduced in mutant myoblasts com-
pared with controls. These results were further supported
by western blot in which we found a reduction of the dif-
ferentiation markers myosin heavy chain and myogenin in
TRIM32V591M muscle compared with controls (Fig. 4d).
TRIM32C39LfsX17 myoblasts showed an extremely slow
growth due to the reduced proliferation that precluded
the production of enough cells for these experiments.
Taken together, our data suggests that the loss of TRIM32
protein due to different mutations reduced myoblast pro-
liferation and delayed myogenic differentiation.
TRIM32 mutations in humans lead to premature
senescence of myoblasts
As mentioned, altered myogenesis and premature senes-
cence are postulated to underlie myopathy in LGMD2H.
Aging of muscle is characterized by functional impair-
ment, loss of quiescence and reduction of the pool of
satellite cells leading to altered regenerative capacity of
the muscle [6, 45]. Additional features of senescent cells
include overexpression of SA-β-gal [12], and altered
morphology [36]. To study whether the reduced cellular
growth and myotube formation observed in TRIM32
mutant myoblasts were associated with premature senes-
cence, we analyzed the satellite cells pool, the degree of
muscle regeneration and the existence of morphological
and metabolic changes in muscle from patients with
(See figure on previous page.)
Fig. 3 TRIM32 mutant myoblasts exhibit a decrease in cell proliferation. a Quantification of number of primary myoblast (proliferation rate) at 1, 4
and 8 days growing in proliferation medium from family A patients (n = 2), family B patients (n = 2), healthy controls (n = 6) and disease controls
(2 LGMD2B, X-EDMD) (n = 3). The proliferation rate is reduced in TRIM32V591M and TRIM32N217S/F568del myoblasts compared with controls. Data
from 12 to 45 independent fields were analyzed per time point. Mean ± SEM; Kruskal-Wallis with Dunn’s multiple comparisons test. b. Analysis of
primary myoblast proliferation at 8 days growing in proliferation medium using Ki67 as a marker of dividing cells from family A patients (n = 2),
family B patients (n = 2) and healthy controls (n = 6). Immunofluorescence showing double staining, desmin (red) and Ki67 (green). Nuclei were
counterstained with Topro 3 (blue). Quantification of Ki67+ cells revealed a progressive decrease in the percentage of proliferating TRIM32V591M
and TRIM32N217S/F568del myoblasts compared with controls. Data from 14 to 41 independent fields were analyzed per condition. Mean ± SEM;
Kruskal-Wallis with Dunn’s multiple comparisons test. Scale bar, 50 μm
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novel TRIM32 mutations. PAX7 staining (an established
marker for satellite cells in adult skeletal muscle),
showed severe reduction of the satellite cell pool in
TRIM32V591M and TRIM32C39LfsX17 skeletal muscles
compared to controls (Fig. 5a). To evaluate the regenera-
tive activity, muscle sections were stained with an anti-
body to MHC-neo, which is expressed in regenerating
myofibers [40]. Unlike the disease control muscle, no
staining of MHC-neo or few scattered positive myofibers
was detected in muscle samples with mutant TRIM32
(Fig. 5b).
Morphological characterization of TRIM32-mutant
myoblasts was examined by SEM, showing that mutant
myoblasts were larger in size and flatter than controls.
In addition, TRIM32-mutant myoblasts had smaller pro-
jections and a reduction in filopodia, which could re-
strict the cellular mobility compared to control
myoblasts (Fig. 5c). To determine possible metabolic
changes of TRIM32-mutant myoblasts, we quantified
the number of cells positively stained for SA-β-gal activ-
ity. A higher percentage of SA-β-gal positive myoblasts
was observed in TRIM32V591M and TRIM32N217S/F568del
myoblasts compared with control myoblasts (Fig. 5d).
These results suggest that TRIM32-mutant myoblasts
may undergo premature senescence.
Rimmed vacuoles and signs of autophagy activation are
usual findings in muscle biopsies from patients with
mutations in TRIM32
Histological analysis of the muscle biopsies from patients
showed a severe dystrophic pattern encompassing inter-
nalized nuclei, endomysial fibrosis, and necrotic and atro-
phic myofibers. Small vacuoles containing basophilic
material were observed throughout the sarcoplasm in
scattered myofibers from all muscle biopsies examined,
but no empty vacuoles were identified by optical micros-
copy (Fig. 6a), unlike previously described cases of
TRIM32 mutations [19, 28, 42]. Ultrastructural analysis by
TEM showed the vacuoles are membrane-bound, with
many containing amorphous granular material (Fig. 6b).
The presence of membrane-bound vacuoles containing
cytoplasmic degradation products suggests altered au-
tophagy. We examined the cytoplasmic content of
TRIM32-mutant myoblasts by TEM, and increased
numbers of lysosomes and autophagic vacuoles were de-
tected in TRIM32V591M and TRIM32N217S/F568del myo-
blasts compared with controls (Fig. 6c). We observed
numerous electron-dense vacuoles consistent with auto-
lysosomes and many multi-vesicular/lamellated struc-
tures. In addition, immunoblotting for LAMP1, a
lysosomal marker, revealed increased lysosomal content
in TRIM32V591M and TRIM32C39LfsX17 muscle compared
with controls (Fig. 6d). P62/SQSTM1 is a marker of au-
tophagic activity because it directly binds to LC3-II in
the autophagosome membrane. Both LC3-II and P62/
SQSTM1 are selectively degraded by autophagy. West-
ern blot demonstrated a striking reduction of p62/
SQSTM1 level in muscle from the three patients from
family A (Fig. 6e, upper panel), while in the only muscle
sample available from family C was slightly reduced
compared to controls (Fig. 6e, lower panel). Levels of
LC3-II were also reduced in muscles from family A and
C (Fig. 6e, lower panel). On the other hand, patient
myoblasts in culture showed an increase of LC3-II in the
basal state compared to controls, which further increases
when fusion between autophagosomes and lysosomes
was inhibited in the presence of Baf-A1 (Fig. 6f ). To-
gether, these results suggest that increased autophagic
flux is present in TRIM32-related myopathy.
Mutated TRIM32 is degraded by autophagy
Previous studies have shown that the EI24
autophagy-associated transmembrane protein is involved
in autophagy-mediated degradation of RING E3 ubiqui-
tin ligases [11]. As TRIM32 is an E3 ubiquitin ligase, we
analyzed whether the degradation of TRIM32 mutated
protein was dependent on autophagy. For this experi-
ment we used TRIM32V591M myoblasts. After autophagy
was inhibited using Baf-A1, western blot analysis of pri-
mary myoblasts lysates showed that mutant TRIM32
protein level was efficiently rescued (Fig. 6f ). This result
supports that TRIM32V591M is degraded via the autoph-
agy pathway.
Discussion
In an effort to establish if the muscle from patients with
muscular dystrophy due to TRIM32 mutations shows
evidence for the pathogenic mechanism postulated from
(See figure on previous page.)
Fig. 4 TRIM32 mutant myoblasts show impaired differentiation. a-c When primary myoblasts from family A patients (n = 2), family B patients (n =
2), healthy controls (n = 6) and disease controls (2 LGMD2B, X-EDMD) (n = 3) reached confluence, proliferation medium was replaced with
differentiation medium and the myoblasts started to fuse into myotubes, which were analyzed after 4 days of differentiation. a
Immunofluorescence showing double staining of primary myoblasts, desmin (red) and myogenin (green). Nuclei were counterstained with Topro
3 (blue). b The expression of myogenin and c the fusion index were reduced in TRIM32V591M and TRIM32N217S/F568del myoblasts compared with
controls. Data from 10 to 32 independent fields were analyzed per condition. Mean ± SEM; Kruskal-Wallis with Dunn’s multiple comparisons test.
Scale bar, 50 μm. d Western blot analysis of biceps muscle lysates derived from family A patients, family C patient and healthy controls. Myosin
heavy chain and myogenin antibodies show reduced expression in TRIM32V591M and TRIM32C39LfsX17 muscles compared with controls. An anti-
GAPDH blot is included as a loading control
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mouse models of this disease, we studied the skeletal
muscle and myoblasts from three families with a muscu-
lar dystrophy due to mutations involving the NHL,
coiled-coil and RING domains of TRIM32. A common
consequence of all the mutations was the remarkable re-
duction of TRIM32 protein muscle level, regardless of
the type of mutation (frameshift, single amino-acid dele-
tion or missense) and the location within the protein.
This supports a similar underlying pathomechanism for
all of the mutations. We also demonstrated reduced
myoblast proliferation/differentiation and premature
senescence, reproducing the findings that had been seen
in animal models [23, 25, 31, 35]. We have also shown
evidence of autophagy activation, probably involved in
the degradation of the mutated TRIM32.
Experiments in the T32KO mice pointed at TRIM32
as a protein involved in the control of myogenic cell
proliferation/differentiation and satellite cell senescence
due to the accumulation of the TRIM32 substrates
NDRG2 and PIAS4 in skeletal muscle, secondary to the
failure of their ubiquitination by TRIM32 [23, 31]. After
exploring these processes in myoblasts with mutations
affecting different TRIM32 domains that causes loss of
protein, our results identified a significant delay in pro-
liferation and differentiation. The features of premature
senescence demonstrated in muscles from patients with
TRIM32 mutations, including a reduced pool of satellite
cells and increased expression of SA-β-gal, are plausible
consequences of the altered myogenic process. An alter-
ation of myogenesis has been described in other heredi-
tary muscle disorders, as a primary mechanism [43] or
as a concomitant effect associated with, or in the ab-
sence of premature senescence [2, 9, 38]. In the case of
TRIM32 the accumulation of several substrates involved
in different biological processes and the frequent finding
of rimmed vacuoles, support that, in addition to the al-
tered myogenesis, other pathways could be playing a
pathogenic role.
The presence of increased amounts of autophagic vacu-
oles, lysosomes and a high level of LAMP1 in muscle with
mutated TRIM32 pointed to an alteration in autophagy.
Degradation of p62/SQSTM1 is a widely used marker to
monitor autophagic activity because it directly binds to
LC3-II in the autophagosome membrane and is degraded
by autophagy. Decreased level of p62/SQSTM1 in muscle
form TRIM32-myopathy patients supports an increased
autophagy. LC3-II is also degraded by the lysosome along
with the autophagosome content, so a decrease in LC3-II
over time provides an estimate of the autophagic flux.
LC3-II in muscle from our patients showed decreased
LC3-II, which also supports increased autophagy, but
LC3-II amount at a given time point does not necessarily
estimate the autophagic activity. However, the increase of
LC3-II in mutant myoblast culture after Baf-A1 treatment
supports increased autophagic flux. The autophagy in the
muscle with TRIM32 mutations could be activated by dif-
ferent triggers. First, it is well established that autophagy is
essential to maintain the population of satellite cells and
their function [16, 17], and that failure of autophagy in
aged satellite cells causes senescence. It has been demon-
strated that the experimental induction of senescence
leads to mTOR downregulation and autophagy activation
[32, 47]. Therefore, the premature senescence in
LGMD2H muscles could lead to increased autophagy per-
haps offsetting some of the effects of the TRIM32 alter-
ation. On the other hand, the accumulation of substrates
that are no longer ubiquitinated due to loss of the mutated
TRIM32 protein and therefore not degraded by the prote-
asome machinery, could activate autophagy as an alterna-
tive degradation pathway [41]. Further investigations
could clarify this point.
In mature healthy muscle, TRIM32 level is normally
low because it seems to be restricted to satellite cells
[23, 35]. This makes detecting the protein in skeletal
muscle challenging. Nevertheless, we found that the
TRIM32 protein level was markedly reduced in skeletal
(See figure on previous page.)
Fig. 5 TRIM32 mutations seem to lead to premature senescence of myogenic cells. a Immunohistochemistry staining and quantification of Pax7+
satellite cells in skeletal muscle from family A patients (n = 2), family C patient (n = 1), healthy controls (n = 5) and disease controls (LGMD2B,
LGMD1C, LGMD2N, NEM6) (n = 4). Immunostaining for collagen type IV (red) to show the muscle fibers, Pax7 (green) to show the satellite cells
and with Topro 3 staining for the nuclei (blue). Quantification of Pax7+ cells revealed a significant reduction in the number of satellite cells in
TRIM32V591M and TRIM32C39LfsX17 muscles compared with controls. Data from 8 to 31 independent fields were analyzed per condition. Mean ±
SEM; Kruskal-Wallis with Dunn’s multiple comparisons test. Scale bar, 50 μm. b Immunohistochemical staining of MHC-neo of skeletal muscle from
family A patients, family B patients, healthy control and disease control (LGMD1B) revealed a large number of positive regenerating fibers in the
disease control. In contrast, TRIM32 patients showed no positive cells (patients A/II.2, A/IV.3 and B/II.2) or, at most, few scattered positive cells
(patients B/II.3 and C/II.2). Scale bar, 100 μm. c SEM images of myoblasts at 5 days growing in proliferation medium from AIV.3 and BII.3 patients,
and healthy controls. TRIM32V591M and TRIM32N217S/F568del myoblasts were larger than control myoblasts. Higher magnification showed a
reduction in the size of projections and number of filopodia of TRIM32V591M and TRIM32N217S/F568del myoblasts comparing to control myoblasts.
Scale bars, 100 μm: lower magnification view; 2 μm: hyper magnification view. d Immunofluorescence staining and quantification of the
percentage of SA-β-gal+ cells in human myoblasts after 10 days growing in proliferation medium from family A patients (n = 2), family B patients
(n = 2) and healthy controls (n = 2). A higher increment of SA-β-gal+ cells was observed in TRIM32V591M and TRIM32N217S/F568del myoblast cultures
compared to controls, supporting a premature senescence in the muscles with TRIM32 altered function. Data from 8 independent fields were
analyzed per condition. Mean ± SEM; One-way ANOVA with Tukey’s multiple comparisons test. Scale bar, 100 μm
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muscle from patients with the missense mutations, sin-
gle amino acid deletion, or frameshift mutation com-
pared to controls. Data about TRIM32 protein level in
muscle of patients with TRIM32 mutations is scarce. Ex-
pected loss of protein by immunoblot was reported in a
patient compound heterozygous for a large deletion that
removes the whole TRIM32 gene and a frameshift muta-
tion, while heterozygous relatives for either of the muta-
tions showed normal TRIM32 level [5], which is the
same as we found in TRIM32C39LfsX17 muscle. To date,
no reported data exist about the level of TRIM32 in
muscle from patients with TRIM32 missense mutations.
The T32KI mouse model carrying the Hutterite missense
mutation p.D489N shows a severe reduction of TRIM32
by immunoblot, and the same neuromuscular phenotype
as Trim32-null mice [25]. Our results of profound re-
duction of TRIM32 level associated with novel missense
mutations are fully consistent with previous studies
demonstrating a markedly reduced amount of TRIM32
in primary fibroblasts cultured from LGMD2H patients
homozygous for the p.D487N substitution [1]. This find-
ing suggests that the mutant TRIM32 proteins might
undergo degradation. Thus, reduced level of the protein
detected by immunoblot could support the pathogenic
role of future novel TRIM32 missense mutations classi-
fied as variants of unknown significance (VUS), in the
appropriate clinical context [21].
Mutations in the NHL, B-box and coiled-coil domains
of TRIM32 have been previously described [7, 21], but
to date mutations in the RING domain had not been re-
ported. Here, we report that all the mutations are associ-
ated with a loss of protein leading to a muscular
dystrophy. The presenting features were highly variable
regarding severity, proximal/distal distribution and
muscle MRI pattern, but with common histological fea-
tures in all cases. Different phenotypes produced by mu-
tations in TRIM32, even in the same region of the gene,
has similarly been reported in other myopathies associ-
ated with mutation in other genes such as MYH7 [27].
Strikingly, two of the three patients with the mutation
p.C39LfsX17 in the RING domain presented, in addition
to the muscle dystrophy, hypogonadism, hearing loss
and behavioral abnormalities, symptoms typically de-
scribed in the BBS previously associated with a mutation
in the B-box domain [3, 10]. BBS is a rare ciliopathy
characterized by multisystemic manifestations (retinal
degeneration, obesity, polydactyly, renal abnormalities,
hypogonadism, behavioral abnormalities, among others),
but no muscle weakness. Only one family with BBS and
TRIM32 mutation in the B-box domain has been de-
scribed, and symptoms of BBS have not been previously
described in patients with TRIM32 muscular dystrophy.
The variable phenotypes in patients with mutations in
TRIM32 are most likely explained by modifying factors
that have yet to be identified and would have to be stud-
ied in as large a cohort of TRIM32 patients as could be
assembled.
Conclusion
Our results demonstrate a common pathogenic pathway
in the development of muscular dystrophy associated to
TRIM32 mutations which lead to loss or reduction of
the protein. The main effect of TRIM32 mutations is
consistent with alterations of myogenesis which induce a
diminished pool of satellite cells and accelerate the sen-
escence of skeletal muscle. We also demonstrated signs
of autophagy activation, that could be the response to
different triggers but probably collaborating in the
pathogenic process. We also provide clinical evidence of
TRIM32-related myopathy patients presenting muscular
weakness together with BBS clinical manifestations, but
to elucidate responsible factors additional studies must
be carried out. The identification of an increasing num-
ber of VUS, especially missense variants, complicates the
(See figure on previous page.)
Fig. 6 TRIM32 mutations increase autophagy activity. a H&E staining of skeletal muscle from family A patients, family B patients and family C
patient showed internalized nuclei, fibers splitting, fibrosis and atrophy. In some fibers small rimmed vacuoles were found (black arrowheads).
Scale bars, 50 μm: lower magnification view; 20 μm: higher magnification view. b TEM analysis of skeletal muscle from family A patient, family B
patients and family C patient revealed membrane-surrounded vacuoles (white arrowheads), some of them containing slightly electron-dense
amorphous material (black arrowheads).c. TEM images of myoblasts at 8 days growing in proliferation medium from family A patients, family B
patients and healthy controls. Lysosome load and autophagic vacuoles were increased in TRIM32V591M and TRIM32N217S/F568del myoblasts
compared to control myoblasts. Lysosomes (black arrows), autolysosomes filled with partially degraded materials (black arrowheads), multi-
vesicular/lamellated structures (red arrowheads), and fusion of electron-lucent vacuoles generating large vacuoles in the cytoplasm space
(asterisk). Black scale bars, 2 μm; white scale bars, 1 μm. d Western blot analysis of muscle biopsy derived from family A patients, family C patients
and healthy controls. Anti-LAMP1 (lysosome marker) revealed an increment of LAMP1 protein level in TRIM32V591M and TRIM32C39LfsX17 muscles
compared with controls. An anti-GAPDH blot was used as a loading control. e Western blot of muscle biopsy from Family A and C patients. Anti-
p62/ SQSTM1 and LC3-II showed reduced level in TRIM32-related myopathy patients compared to healthy controls. Although P62/SQSTM1 level
in the only muscle sample available from Family C was not so reduced as in Family A, indeed it was slightly reduced since the GAPDH indicates
more protein being present in the lane than the controls. An anti-GAPDH blot was used as a loading control. f Western blot experiments of
primary myoblasts from AIII.2 patient and healthy controls incubated with vehicle or with 1 μM Baf-A1 for 6 h. Anti-TRIM32 antibody revealed that
TRIM32V591M protein level was rescued after treatment with Baf-A1. Anti-LC3 (autophagy marker) showed that degradation of LC3-II was partially
inhibited, whereas LC3-I, as expected, was not affected in the presence of Baf-A1. Anti-GAPDH levels were used as loading control
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diagnostic process of genetic disorders. In the case of
TRIM32 mutations, besides myoblast culture to demon-
strate reduced proliferation and differentiation, which is
not always available, we propose immunoblot to charac-
terized the effect of novel candidate pathogenic variants
on TRIM32 protein level.
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